What it's for (Indications)
- Lignocaine (Lidocaine) Hydrochloride 4% Topical Solution, as exemplified by XYLOCAINE, is primarily indicated for the production of topical anesthesia of accessible mucous membranes.
- This includes areas such as the oral cavity, pharynx, larynx, trachea, esophagus, and genitourinary tract, prior to diagnostic or therapeutic procedures like endoscopy, intubation, or catheterization, where localized pain control is required.
- It is also utilized for the temporary relief of pain, itching, soreness, or discomfort associated with minor skin irritations, minor burns, insect bites, or other superficial dermatological conditions where the skin is largely intact.
- The application serves to numb the area, facilitating patient comfort during minor procedures or alleviating symptoms of localized discomfort without the need for systemic analgesia or injectable anesthetics.
- Its utility is strictly limited to topical application on skin or mucous membranes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of Lignocaine Hydrochloride 4% Topical Solution must be meticulously individualized, taking into account the specific area to be anesthetized, the nature of the procedure, the patient's age, weight, physical status, and the route of administration. For mucous membranes, application typically involves cotton applicators or a spray, with doses generally ranging from 1 to 5 mL (equivalent to 40 to 200 mg of lignocaine). It is critical not to exceed the maximum recommended single dose, which for adults is typically 4.5 mg/kg body weight, up to an absolute maximum of 300 mg (approximately 7.5 mL of 4% solution) within any 24-hour period, to mitigate the risk of systemic toxicity. For skin applications, the solution is applied directly to the affected area. Reapplication should be judicious, ensuring adequate time for metabolism and clearance of the drug. Strict adherence to these guidelines and close patient monitoring are essential, especially when applying to large or compromised skin surfaces. |
Safety & Warnings
Common Side Effects
- Adverse reactions to Lignocaine Hydrochloride 4% Topical Solution are predominantly dose-related and typically arise from excessive plasma concentrations due to overdosage, rapid systemic absorption, or accidental intravascular administration.
- Central Nervous System (CNS) effects may manifest as excitement, nervousness, dizziness, blurred vision, tinnitus, tremors, drowsiness, confusion, seizures, unconsciousness, and respiratory depression or arrest.
- Cardiovascular adverse effects can include bradycardia, hypotension, myocardial depression, and, in severe cases, cardiac arrest.
- Local reactions at the site of application are generally mild and transient, such as irritation, erythema, edema, or pruritus; however, allergic contact dermatitis or other hypersensitivity reactions are possible.
- Other rare systemic side effects can include methemoglobinemia (particularly in specific patient populations or with certain co-administered drugs) or taste disturbances.
- Prompt recognition and management of these potential side effects are crucial for patient safety.
Serious Warnings
- Black Box Warning: **SERIOUS WARNINGS: POTENTIAL FOR SYSTEMIC TOXICITY AND LIFE-THREATENING COMPLICATIONS** Topical application of Lignocaine Hydrochloride 4% Solution, especially when used over large surface areas, on abraded or compromised skin, under occlusive dressings, or for prolonged durations, carries a significant risk of systemic absorption. This can lead to dangerously elevated plasma concentrations of lignocaine, resulting in severe and potentially fatal systemic toxicity. Such toxicity may manifest as severe central nervous system (CNS) effects including seizures, respiratory depression, and coma, and profound cardiovascular effects such as bradycardia, hypotension, myocardial depression, and ultimately, cardiac arrest. Accidental ingestion, particularly by pediatric patients, has been associated with severe adverse events, including seizures, respiratory depression, and death. It is imperative that this product be administered with extreme caution, strictly adhering to recommended dosages, application techniques, and monitoring protocols, to minimize systemic exposure. Close observation for signs and symptoms of systemic toxicity is critical, particularly in vulnerable populations including infants, children, the elderly, and patients with pre-existing cardiac, hepatic, or renal dysfunction. Emergency resuscitation equipment and trained personnel capable of managing severe local anesthetic toxicity should be immediately available during circumstances where systemic absorption is a significant concern.
- Serious warnings associated with Lignocaine Hydrochloride 4% Topical Solution underscore the critical risk of systemic toxicity following excessive absorption.
- This risk is considerably heightened when the solution is applied to large surface areas, to abraded, damaged, or inflamed skin, under occlusive dressings, or for prolonged durations, as these conditions significantly increase systemic drug uptake.
- Such systemic absorption can precipitate severe central nervous system (CNS) and cardiovascular adverse events, including potentially fatal seizures, respiratory depression, coma, and cardiac arrest.
- Particular caution is warranted in patients with significant hepatic or cardiac impairment, as these conditions can reduce lignocaine metabolism and clearance, elevating plasma concentrations.
- Accidental ingestion, particularly by children, can lead to severe toxicity and has been reported to be fatal.
- The solution is not for ophthalmic use.
- Patients with pre-existing neurological disorders, epilepsy, or known sensitivities to amide-type local anesthetics require careful risk-benefit assessment.
- Pregnant and lactating individuals should use this medication only when clearly indicated and under strict medical supervision.
How it Works (Mechanism of Action)
Lignocaine (Lidocaine) is an amide-type local anesthetic that exerts its therapeutic effect by reversibly blocking the initiation and conduction of nerve impulses. Its primary mechanism of action involves stabilizing the neuronal membrane by binding to and inactivating voltage-gated sodium channels. This blockade prevents the influx of sodium ions into the nerve cell, which is essential for depolarization and the propagation of action potentials. Consequently, the transmission of pain signals along nerve fibers is inhibited, resulting in a localized loss of sensation or anesthesia. Lignocaine affects both sensory and motor nerve fibers, with sensory blockade typically preceding motor blockade. The onset and duration of action are influenced by factors such as concentration, pKa, and lipid solubility, which dictate its ability to penetrate nerve sheaths and cell membranes to reach the sodium channels from within. This localized effect provides effective pain relief without altering consciousness.
Commercial Brands (Alternatives)
No other brands found for this formula.